Early intracardiac thrombosis in preterm infants and thrombolysis with recombinant tissue type plasminogen activator

Arch Dis Child Fetal Neonatal Ed. 2001 Jul;85(1):F66-9. doi: 10.1136/fn.85.1.f66.

Abstract

Objectives: To determine the incidence of catheter related thrombosis and to test the efficacy of recombinant tissue type plasminogen activator (rt-PA) in preterm infants.

Study design: From January 1995 to December 1998, echocardiography was performed in the first few days of life in 76 very low birthweight (< or = 1500 g) infants out of a total of 147 having an umbilical catheter placed. When intracardiac thrombosis was diagnosed, rt-PA infusion was performed.

Results: Four infants (5%) developed an intracardiac thrombosis during the first few days of life. In three of them, rt-PA at a dose of 0.4-0.5 mg/kg in a 20-30 minute bolus led to dissolution of the clot. One patient received a three hour infusion after the bolus, at a dose of 0.1 mg/kg/h, with resolution of the thrombus. No systemic effects were observed after rt-PA infusion.

Conclusions: Early thrombosis may occur as a complication of umbilical catheterisation in preterm infants; early echocardiographic detection of this disorder allows complete, safe, and rapid lysis with rt-PA.

MeSH terms

  • Catheterization, Peripheral / adverse effects
  • Coronary Thrombosis / diagnosis
  • Coronary Thrombosis / drug therapy*
  • Coronary Thrombosis / etiology
  • Echocardiography, Doppler
  • Female
  • Fibrinolytic Agents / therapeutic use*
  • Humans
  • Infant, Newborn
  • Infant, Premature
  • Infant, Premature, Diseases / diagnosis
  • Infant, Premature, Diseases / drug therapy*
  • Infant, Premature, Diseases / etiology
  • Male
  • Thrombolytic Therapy / methods*
  • Tissue Plasminogen Activator / therapeutic use*
  • Treatment Outcome

Substances

  • Fibrinolytic Agents
  • Tissue Plasminogen Activator